Advertisement

Four Limb Ischemia: A Severe Case of Heparin Induced Thrombocytopenia

  • Kartik AnandEmail author
  • Ibrahim Ibrahim
Correspondence

Dear Editor,

Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication secondary to exposure to heparin due to the formation of antibodies against complexes of platelet factor 4 (PF4) and heparin [1]. This antibody activates platelets causing venous or arterial thrombosis in nearly half of the cases with HIT [2]. Risk of HIT is 10 times higher after exposure to unfractionated heparin (UF) compared to low molecular weight heparin (LMWH) [3]. Herein, we present a case of a patient developing four limb ischemia secondary to HIT.

A 48 year-old-old previously healthy female presented with nausea and abdominal pain. Imaging reveled a large retroperitoneal mass invading the inferior vena cava (IVC) and extending cranially through the IVC to the right atrium. Endovascular biopsy of IVC mass showed features suspicious for sarcoma. Post procedure she developed bilateral lower extremity deep venous thrombosis for which she was started on therapeutic (full-dose) dose of UF titrated...

Notes

Compliance with Ethical Standards

Conflict of interest

Both authors declare that they have no conflicts of interest.

References

  1. 1.
    Arepally GM (2017) Heparin-induced thrombocytopenia. Blood 129(21):2864–2872.  https://doi.org/10.1182/blood-2016-11-709873 CrossRefGoogle Scholar
  2. 2.
    Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al (2012) Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e495S–e530S.  https://doi.org/10.1378/chest.11-2303 CrossRefGoogle Scholar
  3. 3.
    Rice L (2017) HITs and misses in 100 years of heparin. Hematology Am Soc Hematol Educ Program 2017(1):667–673.  https://doi.org/10.1182/asheducation-2017.1.667 Google Scholar
  4. 4.
    Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4(4):759–765.  https://doi.org/10.1111/j.1538-7836.2006.01787.x CrossRefGoogle Scholar
  5. 5.
    Hicks LK, Bering H, Carson KR, Haynes AE, Kleinerman J, Kukreti V et al (2014) Five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program 2014(1):599–603.  https://doi.org/10.1182/asheducation-2014.1.599 CrossRefGoogle Scholar
  6. 6.
    McGowan KE, Makari J, Diamantouros A, Bucci C, Rempel P, Selby R et al (2016) Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program. Blood 127(16):1954–1959.  https://doi.org/10.1182/blood-2015-07-660001 CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Houston Methodist Cancer Center/Weill Cornell MedicineHoustonUSA
  2. 2.Division of Hematology and Oncology, Department of Internal MedicineUniversity of Texas SouthwesternDallasUSA

Personalised recommendations